53 results about "Marburg virus" patented technology

Provided are compounds, methods, and pharmaceutical compositions for treating Filoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula IV:The compounds, compositions, and methods provided are particularly useful for the treatment of Marburg virus, Ebola virus and Cueva virus infections.

Novel antiviral compounds of Formulae (I)-(III) are provided: (I) (II) (III) The inventive compounds, pharmaceutical compositions thereof, and kits including the inventive compounds are useful for the prevention and treatment of infectious diseases caused by viruses, for example, by Flaviviridae virus (e.g., Dengue virus (DENY)), Kunjin virus, Japanese encephalitis virus, vesicular stomatitis virus (VSV), herpes simplex virus 1 (HSV-1), human cytomegalovirus (HCMV), poliovirus, Junin virus, Ebola virus, Marburg virus (MARV), Lassa fever virus (LASV), Venezuelan equine encephalitis virus (VEEV), or Rift Valley Fever virus (RVFV).

Genetic vaccines and methods are provided for enhancing the immunity of a host such as a human to one or more pathogens. In one aspect, a method of enhancing the immunity of a host to a pathogen is provided. The method comprises administering to the host a recombinant virus comprising an antigen sequence that is heterologous to a native progenitor of the recombinant adenovirus and encodes a viral antigen from a pathogenic virus, expression of which is under the transcriptional control of a first promoter; and a cytokine sequence that is heterologous to the native progenitor of the recombinant adenovirus and encodes a cytokine, expression of which is under the transcriptional control of a second promoter. Expression of the antigen and cytokine sequences elicits an immune response directed against the viral antigen upon infection of the host by the recombinant virus. The method can be used for immunizing a host against a wide variety of pathogen viruses, such as HIV, Ebola virus, Marburg virus, hepatitis B virus, hepatitis C virus, influenza virus, human simplex virus, human papilloma virus and respiratory syncytial virus.

Provided are methods of preparing compounds and pharmaceutical compositions for treating Filoviridae virus infections The compounds, compositions, and methods provided are particularly useful for the treatment of Marburg virus, Ebola virus and Cueva virus infections.

Herein disclosed are rapid real-time isothermal multiplex methods of detecting, identifying and quantifying bacterial, viral, and protozoan nucleic acids in a sample. These include contacting the sample with two or more sets of pathogen-specific reverse transcription loop-mediated isothermal amplification primers and novel oligofluorophores specific for the target bacterial, viral, and parasitic nucleic acids of interest such as human immunodeficiency virus, Ebola virus, Marburg virus, Yellow fever virus, hepatitis-B virus, Lassa fever virus, Plasmodium, hepatitis-C virus, hepatitis-E virus, dengue virus, Chikungunya virus, Japanese Encephalitis virus, Middle Eastern Respiratory Syndrome Corona virus, Mycobacterium, West Nile virus, Cytomegalovirus, Parvovirus, Leishmania, Trypanosoma, and Zika virus nucleic acids, under conditions sufficient to produce detectable real-time amplification signals in about 10 to 40 minutes. The amplification signals are produced by pathogen-specific fluorogenic labels included in one or more of the primers. Also, novel reaction and sample lysis buffers, primers, and kits for rapid multiplex detection, quantification, and identification of bacterial, viral, and protozoan nucleic acids by real-time isothermal amplification are herein disclosed.

This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of Ebolavirus (EBOV) or Marburg virus (MARV).

The invention discloses a fluorescence quantitative polymerase chain reaction (PCR) new method for detecting multiple viruses of yellow fever, dengue fever and epidemicencephalitis B and multiple virus detection PCR system consisting of primers, probes, a Premix Ex Taq reaction solution and a sterilized Tris buffer. With good singularity and high sensitivity, three pairs of primers and probes are very suitable for simultaneously detecting viruses of yellow fever, dengue fever and epidemicencephalitis B. And there is no cross reaction between the primers and probes and several other entomophily hemorrhagic fever viruses, such as Marburg virus and Rift Valley fever virus.

The invention discloses an RPA technology-based marburg virus detection kit and an application thereof. An experiment proves that a target gene can be effectively amplified by an RPA primer and a probe of a marburg virus, the specificity reaches 100% and sensitivity is 1*10<2>copies / reaction; and the virus can reach the level equivalent to the sensitivity of fluorescent quantitative PCR, and has no cross reaction with a zaire ebola pseudovirus, a dengue virus, a hemorrhagic fever virus with renal syndrome and a Xinjiang hemorrhagic fever virus nucleic acid. The RPA isothermal amplification system is fast in reaction and wide in temperature range, effective amplification of a target gene can be achieved under the condition of 37-42 DEG C, the method can be used for fast field detection of an infectious nucleic acid of the marburg virus, and an available fast detection method is provided for field screening of a pathogen; and meanwhile, the marburg virus detection kit also has the important significance in prevention of infection transmission of the marburg virus in China and inspection and quarantine in affected areas and entry and exit ports.

The invention provides a multiplex fluorescent polymerase chain reaction (PCR) kit and primers for detecting Ebola viruses, Marburg viruses, Lassa viruses and Rift Valley fever viruses. The multiplex fluorescent PCR kit comprises conventional reagents of an RT-PCR buffer and an RT-PCR enzyme mixed liquor and also comprises primers and probes for detecting the four viruses, wherein the primers are shown in sequences of SEG ID NO: 1-13 and the probes are shown in sequences of SEQ ID NO: 14-18. The multiplex fluorescent PCR kit, the primers and the probes realize rapid and accurate detection of pathogens of Ebola hemorrhagic fever, Marburg hemorrhagic fever, Lassa fever and Rift Valley fever, prevent the four infectious diseases from spreading into or out of the frontier port, are accurate and effective, have strong operability, and can be used for detection of the infectious diseases. Through the multiplex fluorescent PCR kit, the primers and the probes, suspect cases can be found timely and a capability of preventing the infectious diseases from spreading into our country is improved.

Organic compounds showing the ability to inhibit viral glycoprotein (GP)-mediated entry of a filovirus into a host cell are disclosed. The disclosed filovirus entry inhibitor compounds are useful for treating, preventing, or reducing the spread of infections by filovirus including the type species Marburg virus (MARV) and Ebola virus (EBOV). Preferred inhibitors of the invention provide therapeutic agents for combating the Ivory Coast, Sudan, Zaire, Bundibugyo, and Reston Ebola virus strains.

The invention relates to a hemorrhagic fever associated pathogen identifying gene chip; the preparation method comprises preparation of a specific primer, preparation of a pathogen specific oligonucleotide probe, preparation of an oligonucleotide chip, establishment of an RT-PCR (reverse transcription-polymerase chain reaction) system and establishment of a hybrid system and a signal detection method. The gene chip prepared by the invention can be used for simultaneously identifying 16 hemorrhagic fever associated pathogen microorganisms, including Zaire Ebola virus, Sudan Ebola virus, marburg virus, lassa virus, junin virus, Machupo virus, rift valley fever virus, Crimea-Congo hemorrhagic fever virus, plasmodium, hantaan virus, SFTS (severe fever with thrombocytopenia syndrome) virus, dengue virus, yellow fever virus, Chikungunya virus, influenza A virus and influenza B virus. The gene chip has the characteristics of being rapid and accurate, high in throughput and high in sensitivity; and a new technological means is offered for the diagnosis of hemorrhagic fever pathogen, health supervision and the control and prevention of infectious diseases.

The present invention relates to methods for treating systemic inflammation. In certain embodiments, the method comprises administering a therapeutically effective amount of curcumin-selenium loaded nanoparticles. The curcumin-selenium loaded nanoparticles can comprise a matrix of chitosan, polyethylene glycol and tetramethoxysilane encapsulating curcumin and selenium. In certain embodiments, the method comprises administering a therapeutically effective amount of nitric oxide-releasing nanoparticles. The nitric oxide-releasing nanoparticles can comprise a matrix of chitosan encapsulating nitric oxide. In certain embodiments, the systemic inflammation can be caused by endotoxemia. In certain embodiments, the systemic inflammation can be caused by a Filovirus, including an Ebola virus or a Marburg virus. In certain embodiments, the methods for treating systemic inflammation in a subject result in the reduction of proinflammatory cytokines in a subject. In certain embodiments, the method of treatment is a combination therapy. The present invention also relates to methods of making compositions comprising nanoparticles.

The present disclosure discloses a primer probe set and a kit using recombinase polymerase amplifying for detecting Marburg virus and a detection method. The primer probe set includes primers with nucleotide sequences shown in SEQ ID NO. 1 to 2 and a probe with a nucleotide sequence shown in SEQ ID NO.3. The present disclosure also provides the kit using recombinase polymerase amplifying for detecting the Marburg virus. The kit includes the primer probe set. The primer probe set and the kit significantly improve the sensitivity, specificity, and simplicity of the detection of the Marburg virus.

The invention discloses a novel Marburg virus fluorescent quantitative PCR (Polymerase Chain Reaction) detection method and a Marburg virus PCR detection system. The system consists of a primer, a probe, Premix Ex Tag reaction liquid and sterilized Tris water. The primer and the probe have high detection specificity and high sensitivity, are very suitable for the Marburg virus, and do not undergoany cross reaction with an Ebola virus.

The present invention provides compositions comprising peptides derived from amino acid sequences (or from combinations thereof) of fusion and other protein regions of various viruses, including but not limited to, severe acute respiratory syndrome coronavirus, herpesvirus saimiri, human herpesvirus 6, Lassa virus, lymphocytic choriomeningitis virus, Mopeia virus, Tacaribe virus, Friend murine leukemia virus; human T lymphotropic virus type 1; herpesvirus ateles; Marburg virus; Sudan Ebola virus; Zaire Ebola virus, and comprising L- and / or D-amino acids and combinations thereof, which affect T cells by acting on the T cell antigen receptor (TCR). More specifically, the peptides act on the TCRαβ-CD3δε-CD3γε-ζζ signaling complex. Yet more specifically, the peptides act on the TCRα / CD3δε / ζζ signaling module of TCR. The present invention further relates to the prevention and therapy of various T cell-related disease states involving the use of these compositions. Specifically, the compositions are useful in the treatment and / or prevention of a disease or condition where T cells are involved or recruited. The compositions of the present invention also are useful in the production of medical devices comprising peptide matrices (for example, medical implants and implantable devices).

Embodiments of the present invention relate generally the use of certain compositions, e.g., compositions comprising a glutathione precursor and a selenium source, in the therapy of viral diseases and / or reducing the incidence of viral diseases. Related embodiments of the present invention relate to treatment and / or reducing the incidence of respiratory ailments caused by respiratory syncytial virus (RSV) or hemorrhagic fever (EHF) caused by Ebola viruses (EBV) or Marburg virus. Yet in other embodiments, the invention relates to reducing metal toxicity in a biological system, which involves contacting the biological system with a composition comprising a glutathione precursor and a selenium source, optionally together with a chelating agent, an antioxidant, a metallothioneine protein or a fragment of metallothioneine.

The invention discloses an antigen fragment and a truncated protamine based on Marburg virus envelope protein and application. The antigen fragment GP2 provided by the invention has antigen potential similar to GP protein and a neutralizing antibody generated by immunization can be used for effectively inhibiting infection of viruses. Compared with a complete GP protein antigen, the antigen fragment does not have a biological function of the GP protein, so that the viruses cannot enter host cells; when the segment is used for constructing virus-vectored vaccines, the segment has better safety and is more convenient for preparation of multivalent vaccines.

Methods and compositions are provided for at least slowing the progression of a filovirus mediated disease condition in a host. In the subject methods, an effective amount of an agent that at least reduces the amount of folate receptor mediated filovirus cell entry is administered to the host. The subject methods find use in both the prevention and treatment of filovirus associated disease conditions, including Marburg and Ebola-Zaire virus mediated disease conditions.

The present invention relates to compositions containing a PIKfyve inhibitor, preferably apilimod, APY0201 or YM-201636, most preferably apilimod, for use in treating or preventing viral infections, preferably Ebola or Marburg virus infections. It also relates to a pharmaceutical pack or kit comprising apillimod and at least one additional anti-viral agent.

The present invention relates to an improved filovirus vaccine comprising a recombinant modified vaccinia virus Ankara-based (MVA-based) vaccine against filovirus infection and to related products, methods and uses. Specifically, the present invention relates to genetically engineered (recombinant) MVA and FPV vectors comprising at least one heterologous nucleotide sequence encoding an antigenic determinant of a Marburg virus (MARV) or Ebola virus glycoprotein. Specifically, the invention relates to recombinant MVA comprising Ebola virus glycoprotein and virion protein 40. The invention also relates to products, methods and uses thereof as well as prime / boost regimens of MVA and genetically engineered (recombinant) FPV, e.g., suitable to induce a protective immune response in a subject.

The invention relates to a rapid and sensitive method for detection of Marburg virus RT-LAMP. The detection method of the invention employs specific primers design, loop mediated isothermal amplification (LAMP) technique, and fluorescent visual reagent for simple and fast detection of amplification products. The method includes: specimen RNA extraction, RT-LAMP amplification, and interpretation of results. The method can conduct fast and sensitive detection of Marburg virus, uses simple equipment and operations and has less testing time. The invention can greatly improve the detection efficiency of the inspection and quarantine officers in the front line of import and export ports, and can reduce the workload, and solve the positive leak detection in the traditional detection method by the maximum, so as to maximally prevent the introduction of Marburg virus.

Methods and compositions are provided for at least slowing the progression of a filovirus mediated disease condition in a host. In the subject methods, an effective amount of an agent that at least reduces the amount of folate receptor mediated filovirus cell entry is administered to the host. The subject methods find use in both the prevention and treatment of filovirus associated disease conditions, including Marburg and Ebola-Zaire virus mediated disease conditions.